CEO has stated at least two times recently (from what I can recall) that US partnerships were contingent on them getting approval first. And yes, I will be holding them all past (hopefully) FDA approval and (hopefully, again) EMA approval end of year.
I'm playing loads of other stocks---so thankfully I'm not entirely dependent on this, "going to the moon", but if this first drug is approved even with the uber restrictive REMs, it opens the door to all of their other drugs in the pipeline and hundreds upon hundreds more. Now that MAPP is delayed, we are the only game in town close to getting FDA approval. Let's see that 120 day EMA update, then we will see.
Market Data 
Markets 
AI
